This research study will look at the potential safety and effectiveness of an investigational therapy in addressing some of the symptoms of osteoarthritis (OA) of the knee. “Investigational” means the study therapy has not been approved by any regulatory agency, including the U.S. Food and Drug Administration (FDA). Some participants will receive a placebo, which has no active properties (this is sometimes known as a “sugar pill”).
The study therapy is an investigational gene therapy in which healthy cells that form the cartilage, called chondrocytes, are injected into the knee. These cells are designed to potentially reduce knee pain and improve knee function. The study therapy will be given as an injection. A medical professional will carefully insert a needle into your knee using an imaging device to help guide them.
The ACTiVION-II study will last for about 24 months, divided into 3 periods:
Screening
Receive tests and assessments to confirm you qualify for the study, including blood and urine tests,
imaging tests, and questionnaires.
Administration of Study Therapy
Receive your injection. You will remain at the study clinic for 2 hours afterward so the study team can check your health.
Follow-up
Visit the study clinic for tests and assessments. You will have visits
1 day, 1 week, and 1 month after your injection, and then 6 times over the next 24 months. You will then be asked
to participate in a Long-Term Follow-up study to monitor your progress for up to 15 years. If you do not want to participate in the Long-Term Follow-up study, then you will be asked to answer questions about your health for 13 years.
Criteria:
You may qualify for the study if you meet the following requirements:
- Are 40 years of age or older
- Have OA symptoms of a certain severity
- You will be asked to rate your pain, mobility, and other symptoms during the Screening
Note: additional criteria apply.
If you qualify, you may also be invited to participate in a Long-Term Follow-up study of 15 years. If you choose not to participate in
this study, you will be contacted once a year for 13 years to answer a questionnaire about your health.